Monoclonal antibodies combined with adenovirus-vectored interferon significantly extend the treatment window in ebola virus-infected guinea pigs

Xiangguo Qiu, Gary Wong, Lisa Fernando, Jane Ennis., Jeffrey D. Turner, Judie D. Alimonti, Xiaojian Yao, Gary P. Kobinger

Research output: Contribution to journalArticlepeer-review

Abstract

Monoclonal antibodies (MAbs) are currently a promising treatment strategy against Ebola virus infection. This study combined MAbs with an adenovirus-vectored interferon (DEF201) to evaluate the efficacy in guinea pigs and extend the treatment window obtained with MAbs alone. Initiating the combination therapy at 3 days postinfection (d.p.i.) provided 100% survival, a significant improvement over survival with either treatment alone. The administration of DEF201 within 2 d.p.i. permits later MAb use, with protective efficacy observed up to 8 d.p.i.

Original languageEnglish (US)
Pages (from-to)7754-7757
Number of pages4
JournalJournal of virology
Volume87
Issue number13
DOIs
StatePublished - Jul 2013
Externally publishedYes

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Insect Science
  • Virology

Fingerprint

Dive into the research topics of 'Monoclonal antibodies combined with adenovirus-vectored interferon significantly extend the treatment window in ebola virus-infected guinea pigs'. Together they form a unique fingerprint.

Cite this